Initial findings from the AIRFLOW 2 phase II clinical trial suggest targeted lung denervation (TLD) could reduce symptoms of chronic obstructive pulmonary disease (COPD) by more than 50 per cent in patients already receiving aggressive medical therapy.
The multicentre study of 82 patients reported that, three to six months after treatment, 32 per cent of participants who received TLD experienced an adverse COPD-related adverse event compared to 71 per cent of those who received a sham procedure. The benefit continued, with respiratory-related hospitalisation in the first year reducing by more than half versus the sham arm.
Presenting the results at the European Respiratory Society (ERS) International Congress this week, principal investigator, Dr Dirk-Jan Slebos from The Netherlands, said: “We have been able to significantly reduce chronic respiratory symptoms such as shortness of breath, exacerbations of the disease, infections and hospitalisations in a group of COPD patients who are already on aggressive medical therapy.
"There was also a trend towards improved quality of life and better lung function in the treated patients. This has important implications for patient quality of life, and also healthcare costs, as these are events that have a significant impact on the cost of caring for these patients,” he said.